Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check4 days agoChange DetectedAdded a dedicated Locations section listing study sites by state (CA, CO, MA, MI, NY, OH, TX) as part of revision 3.3.3 and removed the individual state Location subsections. The HHS Vulnerability Disclosure link was removed in revision 3.3.2.SummaryDifference0.8%

- Check11 days agoNo Change Detected
- Check18 days agoNo Change Detected
- Check33 days agoChange DetectedAdded a note clarifying that publications are automatically filled from PubMed and may not be about the study. Updated the revision label to v3.3.2, replacing the previous v3.2.0.SummaryDifference0.1%

- Check40 days agoChange DetectedThe government funding lapse notice about NIH operations, previously displayed on the page, has been removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.3%

- Check54 days agoChange DetectedTwo screenshots show only minor layout and timestamp differences. No substantive content changes to core study details (objectives, eligibility criteria, or outcomes) are visible.SummaryDifference0.3%

- Check83 days agoChange DetectedSummary of changes: Deleted the GI/RDI Genetic and Rare Diseases resource for Differentiated thyroid carcinoma and added a government-operating-status notice with a v3.2.0 update.SummaryDifference2%

- Check90 days agoChange DetectedThe page update adds the new version tag v3.1.0 and removes the old v3.0.2 tag, signaling a software version upgrade.SummaryDifference0.1%

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.